US payers are seeking tools for managing orphan drug costs in a way that more explicitly ties pricing to value. This is relatively uncharted territory in the US, where the prices set by manufacturers for drugs targeting few patients have generally been considered non-negotiable.
Cost pressures on payers are growing, driven by a significant acceleration in orphan drug approvals, as well as increasing prices...







